Greenstein V C, Holopigian K, Siderides E, Seiple W, Carr R E
Department of Ophthalmology, New York University Medical Center, New York 10016.
Invest Ophthalmol Vis Sci. 1993 Jan;34(1):269-73.
To study the effects of acetazolamide on central and peripheral visual function in patients with retinitis pigmentosa (RP) who showed no evidence of macular edema.
Thirteen patients with retinitis pigmentosa participated in a preliminary study. Measures of central and peripheral visual function were obtained before and after an 8 wk period on acetazolamide. An additional 10 patients participated in a cross-over study. They were placed on a placebo for an 8 wk period, then on acetazolamide for a second 8 wk period.
None of the patients in the preliminary study showed significant changes in visual acuity, color vision, foveal cone pathway sensitivities, focal electroretinogram (ERG) amplitudes, or in any ERG parameter. Three patients, however, showed significant changes in visual field area and in dark-adapted thresholds. None of the patients in the cross-over study showed significant increases in visual field area.
Given the results and the reports of side-effects, it is difficult to justify using acetazolamide to improve retinal function in RP patients who show no evidence of cystoid macular edema.
研究乙酰唑胺对无黄斑水肿迹象的视网膜色素变性（RP）患者的中枢和周边视觉功能的影响。
13例视网膜色素变性患者参与了一项初步研究。在服用乙酰唑胺8周前后，分别测量中枢和周边视觉功能。另外10例患者参与了一项交叉研究。他们先服用8周安慰剂，然后再服用8周乙酰唑胺。
初步研究中的患者无一例在视力、色觉、中央凹视锥细胞通路敏感度、局部视网膜电图（ERG）振幅或任何ERG参数方面出现显著变化。然而，有3例患者在视野面积和暗适应阈值方面出现了显著变化。交叉研究中的患者无一例视野面积有显著增加。
鉴于这些结果以及副作用报告，对于无黄斑囊样水肿迹象的RP患者，使用乙酰唑胺改善视网膜功能难以得到合理的解释。
